Searched for
INSULIN MANUFACTURING FACILITY
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...
- Biocon Biologics' Malaysia insulin facility classified by US FDA for official actionBiocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...
- Biocon Biologics gets eight observations from USFDA for Malaysia insulin facilityThe US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for ...
- Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
- Biocon Biologics wins $90 mn contract from Malaysia to supply human insulinBiocon has a insulins manufacturing facility is Malaysia at Johor which has been approved by the National Pharmaceutical Regulatory Authori...
- Biocon says probe on Malaysia manufacturing unit ends“This is to inform you that Biocon Sdn Bhd, a subsidiary of Biocon, has received the EIR from the USFDA for the pre-approval inspection of ...
- Biocon gets 3 USFDA observations for insulin facility in MalaysiaUSFDA had conducted a pre-approval inspection of Biocon's subsidiary Biocon Sdn BHd's manufacturing facility in Malaysia for Insulin Glargi...
- USFDA issues response letter for new drug application for insulin glargine: BioconBiocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.
- Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facilityThe integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...
- Biocon slips over 2% on 6 USFDA observationsUS health regulator issued six observations in Form 483 after pre-approval inspection of its insulin drug substance manufacturing facility ...
- Novo Nordisk India and Torrent Pharma expand their insulin manufacturing facilityTorrent Pharmaceuticals and Novo Nordisk began their partnership 25 years ago in 1992 with the manufacture and launch of insulin in 40 IU v...
- Biocon's insulin facility in Malaysia clears inspections for European marketThe facility, set up with an investment of $275 million, is designed to manufacture recombinant human insulin and insulin analogs for the g...
- Biocon bags Rs 460-crore contract from MalaysiaThe drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...
- Malaysian facility to be commercialised in H2 FY17: BioconInitially, the products from the facility will cater to local markets but they would be taken gradually to global markets, Kiran Mazumdar-S...
- Biocon opens facility to produce devices for insulin portfolioSpread over 10,000 square feet, the facility will manufacture pen like delivery devices for people with diabetes in India and other parts o...
- Sanofi to set up insulin facility in TelanganaSanofi, though its Indian entity Shantha Biotechnics, will set up an insulin production facility in Telangana, involving an investment of R...
Load More
